Dheepa Ramasamy
Internal Medicine · Houston, TXNPI 1790926483
Payments from drug & device makers
Across 394 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$781
- AbbVie$717
- Boehringer Ingelheim$611
- Lilly USA, LLC$484
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
- plus $3K from 41 others
What the payments were for
- Food & beverage$7,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,227 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $97,650 |
| MounjaroTirzepatide | 33 | $51,741 |
| ProliaDenosumab | 22 | $38,294 |
| RelistorMethylnaltrexone Bromide | 13 | $30,181 |
| JanuviaSitagliptin Phosphate | 18 | $25,591 |
| EliquisApixaban | 27 | $24,987 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $24,371 |
| TrulicityDulaglutide | 13 | $22,496 |
| FarxigaDapagliflozin Propanediol | 13 | $18,099 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $11,972 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $11,778 |
| MyrbetriqMirabegron | 17 | $10,223 |
| Rosuvastatin Calcium | 348 | $4,808 |
| Atorvastatin Calcium | 311 | $3,723 |
| Olmesartan Medoxomil | 119 | $3,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $781 | $97,65048 claims |
| Lilly USA, LLCMounjaro, Trulicity | $484 | $74,23746 claims |
| AmgenProlia | $315 | $38,29422 claims |
| MerckJanuvia, Janumet Xr | $51 | $37,36936 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $335 | $30,18113 claims |
| PfizerEliquis | $303 | $24,98727 claims |
| GSKTrelegy Ellipta | $322 | $24,37113 claims |
| AstraZenecaFarxiga | $1,074 | $18,09913 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $10,22317 claims |
| AbbVieSynthroid | $717 | $1,05320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.